8th May 2014 15:40
LONDON (Alliance News) - GlaxoSmithKline PLC Thursday said that it has been granted marketing authorisation in Europe for Anoro Ellipta, as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease.
Anoro Ellipta is a once-daily combination treatment, which provides a new alternative for chronic obstructive pulmonary disease patients for whom dual bronchodilator treatment in a single inhaler may be appropriate.
Glaxo said that Anoro Ellipta is now licensed across 31 European countries for the treatment of chronic obstructive pulmonary disease.
Under the terms of a collaboration agreement with the US's Theravance Inc for the treatment, Theravance is obligated to make a milestone payment to Glaxo of USD15 million following marketing authorisation for UMEC/VI by the European Commission. A further USD15 million payment to Glaxo will follow the launch of UMEC/VI in Europe, Glaxo said.
Glaxo said the first launch is expected to take place in Europe in the second or third quarter, with additional launches to follow thereafter.
"A further positive outcome from the collaboration between Theravance and GlaxoSmithKline to bring to market new respiratory medicines that meet patient needs," said Theravance Chief Executive Officer Rick Winningham.
Glaxo shares were down 0.9% at 1,615 pence Thursday afternoon.
By Rowena Harris-Doughty; [email protected]; @rharrisdoughty
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline